Examines liposomal irinotecan with fluorouracil and leucovorin to treat advanced biliary tract cancer, indicating its potential as a new option.
Biliary tract cancers (BTCs) are aggressive malignancies often diagnosed at advanced stages, with limited therapeutic options after progression on gemcitabine-cisplatin (GP) therapy. While liposomal irinotecan with fluorouracil and leucovorin (Nal-IRI/FL) has shown efficacy in prior trials, outcomes have been inconsistent, and real-world data remain limited.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: